Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahima Jamal

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Seminars in Immunology|April 1, 2023
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncologyRahima Jamal, Meriem Messaoudene, Marina de Figuieredo, et al.
Gynecologic Oncology Reports|September 20, 2023
Primary malignant melanoma of the vagina: A case reportGiancarlo Sticca, Bojana Misheva, Herawaty Sebajang, et al.
NDT Plus|May 19, 2015
Permanent renal failure induced by pentastarchRahima Jamal, Marc Ghannoum, Jean-Francois Naud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2016
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17Rachel A Goodwin, Rahima Jamal, Christopher M Booth, et al.
Gynecologic Oncology|August 14, 2013
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancerRachel A Goodwin, Rahima Jamal, Dongsheng Tu, et al.
Investigational New Drugs|June 5, 2024
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomasRandeep Sangha, Rahima Jamal, Jennifer Spratlin, et al.
Investigational New Drugs|August 20, 2025
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumorsJudy S Wang, Edward R Arrowsmith, J Thaddeus Beck, et al.
Scientific Reports|September 5, 2020
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patientsMarina Amaral de Ávila Machado, Cristiano Soares de Moura, Kelvin Chan, et al.
Oncoimmunology|March 26, 2019
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitorsArielle Elkrief, Layal El Raichani, Corentin Richard, et al.
Oncoimmunology|February 24, 2026
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanomaCaroline Lambert, Rahima Jamal, Paméla Thébault, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Seminars in Immunology|April 1, 2023
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncologyRahima Jamal, Meriem Messaoudene, Marina de Figuieredo, et al.
Gynecologic Oncology Reports|September 20, 2023
Primary malignant melanoma of the vagina: A case reportGiancarlo Sticca, Bojana Misheva, Herawaty Sebajang, et al.
NDT Plus|May 19, 2015
Permanent renal failure induced by pentastarchRahima Jamal, Marc Ghannoum, Jean-Francois Naud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2016
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17Rachel A Goodwin, Rahima Jamal, Christopher M Booth, et al.
Gynecologic Oncology|August 14, 2013
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancerRachel A Goodwin, Rahima Jamal, Dongsheng Tu, et al.
Investigational New Drugs|June 5, 2024
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomasRandeep Sangha, Rahima Jamal, Jennifer Spratlin, et al.
Investigational New Drugs|August 20, 2025
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumorsJudy S Wang, Edward R Arrowsmith, J Thaddeus Beck, et al.
Scientific Reports|September 5, 2020
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patientsMarina Amaral de Ávila Machado, Cristiano Soares de Moura, Kelvin Chan, et al.
Oncoimmunology|March 26, 2019
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitorsArielle Elkrief, Layal El Raichani, Corentin Richard, et al.
Oncoimmunology|February 24, 2026
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanomaCaroline Lambert, Rahima Jamal, Paméla Thébault, et al.
Pageof 4